Immunome, Inc. Hits Day Low of $10.02 Amid Price Pressure

Immunome, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 9.33%. The stock reached an intraday low of USD 10.02, reflecting a challenging trading session.
In terms of performance metrics, Immunome's one-day performance starkly contrasts with the S&P 500, which saw a modest decline of 0.28%. Over the past week, however, Immunome has shown some resilience, gaining 3.1%, while its one-month performance stands at 2.37%. Despite these short-term gains, the stock has underperformed significantly over the past year, with a decline of 28.79%, compared to the S&P 500's increase of 15.79%.

The company has recently reported a higher net profit of USD -85.04 million for the first half of the year, alongside a notable reduction in raw material costs by 14.94% year-over-year. However, it continues to face challenges, including a negative EBITDA and a return on equity of -66.22%. With institutional holdings at 100%, the company remains under close scrutiny by investors.